

C1 ESTERASE INHIBITOR [HUMAN] (CINRYZE®) PRESCRIBER ORDER FORM

Patient Name: _____	Date of Birth: _____	Gender: _____
----------------------------	-----------------------------	----------------------

Address: _____

Phone: _____	Height: _____	<input type="checkbox"/> inches <input type="checkbox"/> cm	Weight: _____	<input type="checkbox"/> lbs. <input type="checkbox"/> kg
---------------------	----------------------	---	----------------------	---

Clinical Information

Primary Diagnosis Description: Defects in the complement system (hereditary angioedema)	ICD-10 Code: D84.1
--	---------------------------

C1 Esterase Inhibitor [Human] (Cinryze®) Prescription

C1 Esterase Inhibitor [Human] (Cinryze®) 500 unit vial refill as directed x 1 year

Infuse 1000 units by slow IV injection at a rate of 1 mL/min every 3 to 4 days as directed for prophylaxis of HAE attacks.

Infuse _____ units by slow IV injection at a rate of 1 mL/min every _____ days as directed for prophylaxis of HAE attacks.

Round dose to the nearest whole vial to avoid waste, where applicable.

Dispense _____ doses.

Keep _____ doses on-hand at all times.

Ancillary Orders

Anaphylaxis Kit

Does this patient require an anaphylaxis kit?

Yes, with 1st dose Yes, with all doses

Medication Orders

Other: _____

IV Flush Orders

Peripheral: 0.9% Sodium Chloride 2 to 3 mL pre-/post-use.

Implanted Port: 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use.
For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed.

Skilled nurse to assess and administer and/or teach self-administration, where appropriate, via access device as indicated above. Nurse will provide ongoing support as needed. Refill above ancillary orders as directed x 1 year.

If patient is seen within a provider led infusion clinic, Option Care Health's infusion reaction management policy, skilled nursing plan of treatment, and IV flush administration will be followed per provider oversight. No individual anaphylaxis kit will be dispensed.

I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.

Prescriber Signature: _____ **Date:** _____

Prescriber Information

Prescriber Name: _____	Phone: _____	Fax: _____
Address: _____	NPI: _____	
City, State: _____	Zip: _____	Office Contact: _____

Fax completed form, insurance information, and clinical documentation to: 713-983-4647

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. **IMPORTANT WARNING:** This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.

Not valid for use for patients residing in Arizona, New York, and Wisconsin